戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  underwent pancreaticoduodenal resection for periampullary adenocarcinoma at The Johns Hopkins Hospit
2 IAT recipients had malignancy (pancreatic or periampullary adenocarcinoma in 14).
3 ltivariate analysis of the 443 patients with periampullary adenocarcinoma indicated that the most pow
4                                              Periampullary adenocarcinoma is a major clinical problem
5 ed overall survival in ampullary relative to periampullary adenocarcinoma is due in part to a signifi
6                          Among patients with periampullary adenocarcinoma treated by pancreaticoduode
7              Microarray analysis of SFRP1 in periampullary adenocarcinoma was obtained from the Gene
8  April 1996 and June 2001, 299 patients with periampullary adenocarcinoma were enrolled in a prospect
9 il 1996 and December 1997, 114 patients with periampullary adenocarcinoma were enrolled in an ongoing
10            Of the 242 patients with resected periampullary adenocarcinoma, 149 (62%) were pancreatic
11                 Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, com
12 cause their final pathology failed to reveal periampullary adenocarcinoma, leaving 294 patients for a
13 xists regarding the benefit of resection for periampullary adenocarcinoma, particularly for pancreati
14  frozen section) of margin-negative resected periampullary adenocarcinoma, patients were randomized t
15 perative verification of completely resected periampullary adenocarcinoma, the patients were randomiz
16 ore years ago by pancreaticoduodenectomy for periampullary adenocarcinoma.
17                      Morphologic subtypes of periampullary adenocarcinomas (i.e., pancreatobiliary or
18 rs associated with survival in patients with periampullary adenocarcinomas and to compare survival be
19      In contrast to many other solid tumors, periampullary adenocarcinomas exhibited more frequent ge
20 ations using Affymetrix SNP 6.0 arrays in 60 periampullary adenocarcinomas from Oslo University Hospi
21                                Patients with periampullary adenocarcinomas have widely variable survi
22  prognosticator of survival in patients with periampullary adenocarcinomas than tumor anatomic locati
23                                Patients with periampullary adenocarcinomas undergo the same resection
24                    Survival of patients with periampullary adenocarcinomas was compared by the Kaplan
25  adenocarcinoma was lower than that in other periampullary adenocarcinomas.
26 er, there have been no randomized trials for periampullary adenocarcinomas.
27 vival for patients with pancreatic and other periampullary adenocarcinomas.
28  for some patients with pancreatic and other periampullary adenocarcinomas.
29 71; 11%), neuroendocrine tumor (n = 31; 5%), periampullary adenoma (n = 21; 3%), cystadenocarcinoma (
30 n organs have received particular attention, periampullary and pancreatic incidentalomas (PIs) remain
31                      Incidentally discovered periampullary and pancreatic masses comprise a substanti
32                                              Periampullary bleeding is an uncommon cause of upper gas
33                  Spontaneous, non-iatrogenic periampullary bleeding is extraordinarily rare with only
34 is is the first reported case of spontaneous periampullary bleeding successfully treated with APC.
35         Between 25% and 75% of patients with periampullary cancer who undergo exploratory surgery wit
36 t laparotomy in patients with pancreatic and periampullary cancer with resectable disease based on CT
37 t-effective in pancreatic cancer (but not in periampullary cancer), when laparotomy following diagnos
38 e only curative treatment for pancreatic and periampullary cancer, but many patients undergo unnecess
39  in 10% to 20% of patients with unresectable periampullary cancer.
40 n patients suspected of having pancreatic or periampullary cancer.Keywords: CT, Abdomen/GI, Pancreas,
41                          The distribution of periampullary cancers by site in the reoperative group u
42 r to the 65%, 14%, 16% and 5% for resectable periampullary cancers found in the primary surgery group
43 ents with presumed resectable pancreatic and periampullary cancers.
44 tients are referred to tertiary centers with periampullary carcinoma after their tumors were deemed u
45 mes of patients undergoing reexploration for periampullary carcinoma at a high-volume center.
46 ate that patients undergoing reoperation for periampullary carcinoma have similar resectability, peri
47 tomy and/or palliative surgery for suspected periampullary carcinoma underwent reexploration.
48 9-86 years; 105 men) with pancreatic head or periampullary carcinoma were included.
49  exploratory laparotomy to have unresectable periampullary carcinoma.
50 ergoing surgical palliation for unresectable periampullary carcinoma.
51 d prospectively for patients presenting with periampullary carcinomas to the Memorial Sloan-Kettering
52             Telomerase activity is common in periampullary carcinomas.
53                 Potential mechanisms include periampullary colonization of pathogenic bacteria and me
54 d April 2003, 1595 patients underwent PD for periampullary disease (392 benign, 1203 malignant).
55 lt patients with pancreatic cancer or benign periampullary disease treated from 2014 to 2022.
56 coduodenectomy (PD) for benign and malignant periampullary disease.
57 of patients with pancreatic cancer or benign periampullary diseases is needed.
58 of patients with pancreatic cancer or benign periampullary diseases, an easily applicable risk score
59  for early-stage pancreatic cancer vs benign periampullary diseases, and outperformed CA19-9 (differe
60 ng early-stage pancreatic cancer from benign periampullary diseases.
61 This study aimed to assess the prevalence of periampullary diverticulum (PAD) among endoscopic retrog
62                                              Periampullary diverticulum (PAD) is an incidental findin
63 testine (especially the clinically important periampullary duodenum), ursodeoxycholate had equal effi
64 omerase activity was upregulated in 26 of 33 periampullary malignancies (79%): 17 of 21 pancreatic ad
65 y 1994 and October 1998, 194 patients with a periampullary malignancy underwent exploratory surgery w
66 e ampulla of Vater is the second most common periampullary malignancy.
67 ed safely during pancreaticoduodenectomy for periampullary malignant tumors.
68       Five (1.7%) of 288 patients with other periampullary neoplasms also had a deleterious germline
69 noma, 288 patients with other pancreatic and periampullary neoplasms, and 51 patients with non-neopla
70 s affected by middle-distal obstruction from periampullary neoplasms, in which preoperative drainage
71 pulla of Vater is improved relative to other periampullary neoplasms.
72 s) presented with an incidental finding of a periampullary or pancreatic mass.
73 urrent management of jaundiced patients with periampullary or proximal bile duct neoplasms who are ca
74 uodenectomy (PD) or major hepatectomy due to periampullary or proximal bile duct neoplasms.
75                     The treatment of Type-II-periampullary perforations that develop during endoscopi
76 ectomy for adenocarcinoma of the pancreas or periampullary region over a 3.5-year period were entered
77 ith NF-1, the carcinoids were located in the periampullary region.
78 nant and benign diseases of the pancreas and periampullary region.
79 nant and benign diseases of the pancreas and periampullary region.
80 ant and benign disorders of the pancreas and periampullary region.
81 nts with malignant tumors of the pancreas or periampullary region.
82 ectomy for tumors of the pancreatic head and periampullary region.
83  Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized
84 ncreaticoduodenectomy for the treatment of a periampullary tumor and can lead to exocrine and endocri
85  adenocarcinoma (142 patients, 92%) or other periampullary tumors (12 patients, 8%).
86 nted with pancreatic head adenocarcinoma and periampullary tumors (ampulloma, distal cholangiocarcino
87 reas, and long-term survival rates for other periampullary tumors are approximately 40%.
88                                              Periampullary tumors are neoplasms that arise in the vic
89 n diagnostics, less than 5% of patients with periampullary tumors experience an overall survival of f
90                        Poorly differentiated periampullary tumors had significantly higher telomerase
91  surgery primarily focused on pancreatic and periampullary tumors in order to identify elements assoc
92 l pancreatectomies for primary pancreatic or periampullary tumors were performed between October 2001
93                        Fresh specimens of 62 periampullary tumors were snap-frozen in liquid nitrogen
94  identifies potential prognostic markers for periampullary tumors, the genetic characterization of wh
95                                           In periampullary tumors, the highest rates of resection and
96 for pancreatic head adenocarcinoma and other periampullary tumors.
97 is the only potential curative treatment for periampullary tumours.